30th September 2008

Luminaderm®

Progress continues very positively towards the commercialisation of NovaBiotics Luminaderm® technology assets; peptide and botanical compounds that are ideally suited as anti-infective components of cosmeceutical and consumer health care products.  NovaBiotics board has now selected a short-list of potential commercial partners with whom it wishes to continue discussions and negotiations as regards the continued development of these attractive assets.  A number of options remain open to the Company as regards routes to market in the short term through a number of applications including dandruff, acne, athletes foot, nail care etc.